Hospital Polusa S.A.

Lugo 10 trials 3 recruiting

10 Registered trials

3 Currently recruiting

Organisation

Hospital Polusa S.A.

Location

Lugo, Spain

Identifier

ORG-100047442

Address

Calle Del Doctor Iglesias Otero S/N, San Lazaro Del Puente, 27004, Spain

Departments

Allergy
D10-528 : Nephrology
Nefrologia
Nefrology
Nephrology
Neprology
Servicio de Nefrología

Clinical trials at this site (10)

Search interface

Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Chronic Kidney Disease 4
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting

2025-521661-27-00 Primary Membranous Nephropathy 10 2025-12-19
Atacicept in Multiple Glomerular Diseases Recruiting

2024-518465-10-00 Multiple Autoimmune Glomerular Diseases 4 2025-12-12
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2i Ended

2023-503828-13-00 Nephrology 4 2023-12-12
Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy Ended

2024-514090-21-00 Aetiological treatment of moderate - severe intermitten 5 2020-08-05
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Focal segmental glomerulosclerosis (FSGS) 5 2018-10-15